Emphasizing Shared Decision Making and Emerging Strategies in MS Treatment: Patricia K. Coyle, MD
February 5th 2024The professor of neurology at Stony Brook University Medical Center discussed the significance of shared decision making in multiple sclerosis care and promising developments in treatment strategies. [WATCH TIME: 3 minutes]
Treating RRMS With Anti-CD20 Therapy During COVID-19
May 24th 2021Important considerations regarding the use of anti-CD20 therapies such as ofatumumab to treat relapsing multiple sclerosis during the COVID-19 pandemic and strategies that can help neurologists talk with patients about drug use and COVID-19 vaccinations.
Counseling Patients On High-Efficacy Therapy for RRMS
May 3rd 2021Robert Fox, MD, of the Cleveland Clinic, comments on the advantage of starting treatment with a high-efficacy therapy for relapsing-remitting multiple sclerosis and explains his approach to counseling patients when selecting treatment.
Treating RRMS: Low Vs High-Efficacy Therapy
May 3rd 2021Dr Patricia K. Coyle, of the Stony Brook Neurosciences Institute, comments on her approach to selecting first-line therapy to treat relapsing-remitting multiple sclerosis, explaining how she selects between a lower-risk or high-efficacy therapy.